Cyclosporin in localized and systemic scleroderma--a clinical study.
Four patients with systemic scleroderma and 1 patient with localized scleroderma were treated with ciclosporin (CS), given in daily doses between 2.2 and 5.6 mg/kg body weight for 3-26 months. Under this medication clinical improvement was observed in 4 patients with partial regression of cutaneous sclerosis and inflammation, healing of fingertip ulcerations or leg ulcers and improvement of articular mobility. However, in 1 patient with rapidly advancing systemic scleroderma a short-term therapy with CS in low doses (2-3 mg/kg body weight) resulted in arterial hypertension and renal dysfunction. Therefore careful selection of patients and close-meshed controls are indicated when CS is considered as anti-inflammatory treatment in scleroderma.
Wörle
B
B
Department of Dermatology, Ludwig-Maximilians-Universität München, FRG.
Hein
R
R
Krieg
T
T
Meurer
M
M
D058186:Acute Kidney Injury / Q000139:chemically induced; D000328:Adult; D003404:Creatinine / Q000097:blood; D003524:Cyclosporins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005355:Fibrosis; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D012594:Scleroderma, Localized / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D012595:Scleroderma, Systemic / Q000188:drug therapy* / Q000276:immunology
D003524:Cyclosporins; D003404:Creatinine